P2, N=45, Recruiting, Memorial Sloan Kettering Cancer Center

P1, N=15, Recruiting, Virginia Commonwealth University | Not yet recruiting --> Recruiting | Trial completion date: Oct 2029 --> Oct 2030 | Trial primary completion date: Oct 2027 --> Oct 2028

Similarly, the random weights analysis favored ivosidenib with all evaluated weights and results converging quickly towards the main analysis results. These results provide comprehensive evidence that ivosidenib is an effective treatment with a tolerable safety profile for this aggressive disease, supporting previous data (ClinicalTrials.gov NCT02989857).

P1, N=47, Active, not recruiting, Daiichi Sankyo | Phase classification: P=N/A --> P1

P3, N=468, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting

These results highlight the potential of ¹⁸F-DOPA-PET and advanced MRI sequences as valuable complements to standard RANO 2.0 MRI evaluations for assessing treatment response in glioma patients undergoing IDHi therapy.

P4, N=15, Not yet recruiting, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university

Olutasidenib was well tolerated and conferred disease control in cCS. Study limitations include open-label design and low patient sample due to rarity of cCS.

P=N/A, N=0, Withdrawn, Duke University | N=40 --> 0 | Not yet recruiting --> Withdrawn

This review focuses on contemporary pharmacotherapeutic approaches used in the management of glioblastoma, IDH-wildtype, including temozolomide-based chemotherapy, corticosteroids for edema control, and antiangiogenic therapy in recurrent disease, with particular emphasis on their clinical efficacy and limitations...Particular attention is given to ivosidenib, a selective inhibitor of mutant IDH1, currently evaluated for the treatment of astrocytoma, IDH-mutant, grade 4...Finally, innovative drug-delivery technologies designed to overcome the blood-brain barrier are briefly discussed as complementary strategies that may enhance the efficacy of both conventional and targeted therapies. Overall, future advances in the treatment of diffuse gliomas will likely depend on the integration of molecularly targeted agents, predictive biomarkers, and advanced delivery platforms aimed at improving patient survival and quality of life.

P3, N=365, Recruiting, Nuvation Bio Inc. | Phase classification: P2 --> P3 | N=125 --> 365 | Trial completion date: Mar 2028 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2028

Using these models, we tracked clonal evolution under selective pressure from IDH inhibitors and combination therapies, identifying an association between WT1 mutations and ivosidenib (IDH1 inhibitor) monotherapy resistance, as well as an antagonism between ivosidenib and enasidenib (IDH2 inhibitor) when tested in IDH1-mutated cells. Our findings demonstrate how single-cell proteogenomic analysis of PDX models can illuminate drug resistance mechanisms and inform therapeutic strategies.